Rheumatoid Arthritis (RA) a chronic condition that is estimated to affect around 0,5%. Early RA diagnosis can make a different to the amount of tissue damage, and in this, the detection of autoantibodies against citrullinated proteins/peptide (anti-CCP) has an important prognostic value for the disease.Along with other biomarkers (Rheumatoid Factors) are important in diagnosis of RA patients. Those who develop anti-CCP autoantibodies are very likely to develop RA, however, anti-CCP is not present in all RA patients.
The Svar CCP portfolio consists of enzyme-linked immunosorbent assay (ELISA) for detection and semi-quantitation of IgG antibodies to Cyclic Citrullinated Peptides (CCP).
Manufacturer Svar Life Science AB | Available Worldwide
Be the first to review this product